Riskpilot← Back to searchSign inGet full accessELITE HELSE LABORATORY AS
ASActiveOrg 917364443Landgangen 3, 0252 OsloManufacture of perfumes and toilet preparations · NACE 2042Est. 20160 employees
Revenue 2024
NOK 1,3M
+7% vs 2023
EBITDA margin
-24.8%
-272% vs 2023
Equity ratio
72.6%
Financial strength
Net profit 2024
NOK -247K
-275% vs 2023
| Revenue | NOK 1,3M | +7% |
| EBITDA | NOK -314K | -272% |
| Net profit | NOK -247K | -275% |
| Total assets | NOK 365K | -40% |
| Equity | NOK 265K | -52% |
| Employees | 0 | — |
Legal name
ELITE HELSE LABORATORY AS
Org number
917364443
Legal form
Aksjeselskap
NACE code
2042 · Manufacture of perfumes and toilet preparations
Founded
8. juli 2016
Share capital
NOK 30 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Promotere og informere om helsefremmende produkter og helseinformasjon. Selskapet skal produsere kremer og kosttilskudd samt drive import. Eie fast eindom, eindomsutvikling og utleie av fast eindom, eie aksjer i andre selskap, investere i aksjer og andre verdipapirer, samt annen virksomhet som står i naturlig tilknyttning til dette.
Address
Landgangen 3, 0252 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 470 | 548 | 999 | 1 180 | 1 268 |
| Staff expenses | −0 | −0 | −0 | −1 | −7 |
| EBITDA | 82 | 7 | −9 | 183 | −314 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 82 | 7 | −9 | 183 | −314 |
| Net financials | −1 | 0 | 0 | 0 | 0 |
| Profit before tax | 82 | 7 | −9 | 183 | −314 |
| Tax | 19 | 2 | −0 | 41 | −67 |
| Net profit | 63 | 5 | −9 | 141 | −247 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 536 | 587 | 509 | 607 | 365 |
| Equity | 374 | 380 | 371 | 554 | 265 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 161 | 207 | 138 | 54 | 100 |
| Total debt | 161 | 207 | 138 | 54 | 100 |
EBITDA margin
-24.8%
This company
15.8%
Market median
-257% vs market
20202024
Equity ratio
72.6%
This company
38.2%
Market median
+90% vs market
20202024
Return on equity
-93.1%
This company
18.4%
Market median
-606% vs market
20202024
Net profit margin
-19.5%
This company
8.1%
Market median
-341% vs market
20202024
Asset turnover
3.47×
This company
1.12×
Market median
+210% vs market
20202024
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IB Chief Executive Officer | Chief Executive Officer | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2016 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 70% | 70% | 2022 | |
| Company | 30% | 30% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Suta As
ELITE HELSE LABORATORY AS Board members of ELITE HELSE LABORATORY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Isabella Bukurie Bessières | Chief Executive Officer | 0 companies |
| Laura Suta | Board of Directors | 0 companies |